Navigation Links
Rigel Will Present Clinical Product Portfolio Update at J.P. Morgan Healthcare Conference
Date:1/10/2014

Blood (volume 113, number 14), showed that fostamatinib significantly increased the platelet counts of patients including some who had failed currently available TPO agents and may offer a treatment approach that targets the underlying cause of this disease.  Rigel plans to commence a Phase 3 study in this patient population in the first half of the year.

Immunoglobulin A Nephropathy (IgAN) is an autoimmune disease that severely affects the functioning of the kidneys.  An estimated 12,000 Americans are diagnosed with this type of glomerulonephritis each year, with 25% of its victims eventually requiring dialysis and/or kidney transplantation over time. IgAN is characterized by the deposition of IgA immune complexes in the glomeruli of the kidneys leading to an inflammatory response and subsequent tissue damage that ultimately disrupts the normal filtering function of the kidneys. By inhibiting SYK in kidney cells, fostamatinib may block the signaling of IgA immune complex receptors and arrest or slow destruction of the glomeruli. Rigel expects to enter a Phase 2 study of fostamatinib in patients with IgA nephropathy in the spring of 2014.

R348, JAK/SYK Inhibitor for Dry Eye
Approximately 4 million people in the U.S. suffer with dry eye disease, including an estimated 25% of the patients with rheumatoid arthritis and systemic lupus eryathematosus.  Rigel initiated a Phase 2 clinical study to evaluate the safety and potential efficacy of R348, a topical ophthalmic JAK/SYK inhibitor, aimed at reducing the inflammation responsible for the painful symptoms of this disease.  Results of that study are expected in the second half of 2014.

Additionally, according to an article published by the American Academy of Ophthalmology, a significant number (22-80%) of patients with acute or chronic graft vs. host disease (GvHD) develop a secondary incidence of dry eye (keratoconjunctivitis sicca).   I
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigel to Present at Oppenheimer Healthcare Conference
2. Rigel Announces Third Quarter 2013 Financial Results
3. Rigel Provides Pipeline Update
4. Rigel to Present at Stifel Healthcare Conference
5. Rigel To Focus On ITP, DLE And Dry Eye
6. Rigels R343 Did Not Meet Primary Endpoint in Asthma Study
7. Rigel Announces Second Quarter 2013 Financial Results
8. Rigel Will Resume Responsibility for Fostamatinib Program
9. Rigels R348 to Initiate Phase 2 Clinical Trial in Dry Eye
10. Rigel Announces First Quarter 2013 Financial Results
11. Rigel Announces Fourth Quarter and Year End 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... The controversy surrounding the use of ... (procedures to remove uterine fibroids) continues, as a ... Johnson & Johnson,s Ethicon, Inc. unit, which was ... to the report published by The Wall Street ... is trying to determine what the company knew ...
(Date:5/28/2015)... , May 28, 2015 KaloBios Pharmaceuticals, Inc. ... Ronald A. Martell , to the position of ... of the KaloBios Board of Directors. In this new ... management team to refine and execute on the strategic ... company developing therapeutics for orphan oncology indications with high ...
(Date:5/28/2015)... Calif. , May 28, 2015 Compassion & ... Committee has approved a bill that would authorize the option ... vote was 5-2. ... (SB 128) , would allow mentally competent adults with six ... medication they could take to painlessly and peacefully end an ...
Breaking Medicine Technology:Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 2Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 3KaloBios Appoints Ronald A. Martell Executive Chairman 2KaloBios Appoints Ronald A. Martell Executive Chairman 3KaloBios Appoints Ronald A. Martell Executive Chairman 4KaloBios Appoints Ronald A. Martell Executive Chairman 5California Committee Sends Medical Aid-in-Dying Bill to Senate Floor 2California Committee Sends Medical Aid-in-Dying Bill to Senate Floor 3
... Neuralstem, Inc. (NYSE Amex: CUR ) announced ... trial to test its neuroregenerative small molecule drug, NSI-189, in ... the drug in healthy volunteers for safety and tolerability. Phase ... will test the safety and tolerability of NSI-189 in depressed ...
... Since its initial inception, Echosens has ... and strengthen its product range with the recent introduction ... Equipped with a new and more ergonomic tactile interface, ... latest FibroScan ® provides a reliable, accurate and ...
Cached Medicine Technology:Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial 2Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial 3Echosens: Launch of the FibroScan®502 Touch 2
(Date:5/28/2015)... May 28, 2015 The CEO and ... a just launched blog series which provides analysis on ... on the “R. Bruce Dalglish” profile on Blogger.com, this ... Bruce Dalglish’s corporate experience. , “Throughout my business ... cultures have upon the overall success of businesses,” stated ...
(Date:5/28/2015)... May 28, 2015 More than 300 ... will raise money to help the Muscular Dystrophy Association ... dystrophy and related life-threatening diseases that limit muscle strength ... mobile program. , From June 1 to June 30, ... customers the opportunity to help send local children affected ...
(Date:5/28/2015)... 28, 2015 ZH Healthcare (ZH), a ... it is releasing BlueEHS, the Electronic Health Solution, on ... for the benefit of all AWS users worldwide. ... first of its kind, Freemium, SaaS, Electronic Health Solution ... (EHR) with an integrated practice management system (PMS), e-Rx, ...
(Date:5/28/2015)... CompanionDx , a Houston-based ... it will present their integrated solution of next-generation ... annual American Society of Clinical Oncology (ASCO) in ... DNA in a patient’s tumor via a small ... changes or somatic mutations. Pharmacogenomics testing establishes a ...
(Date:5/28/2015)... Sexual Health Innovations, a nonprofit ... health and wellbeing in the United States, announced ... (USF) will be the first institution to adopt ... reporting system. , Callisto is designed to ... experience for college sexual assault survivors, to give ...
Breaking Medicine News(10 mins):Health News:R. Bruce Dalglish, CEO of Alliance Hospice, Introduces New Blog Series On Positive Corporate Culture 2Health News:sweetFrog and MDA Join Forces to Send Kids with Muscle Disease to Summer Camp 2Health News:sweetFrog and MDA Join Forces to Send Kids with Muscle Disease to Summer Camp 3Health News:BlueEHS, the Electronic Health Solution, now available on Amazon AWS Market place 2Health News:BlueEHS, the Electronic Health Solution, now available on Amazon AWS Market place 3Health News:CompanionDx® Launches Integrated Genomic Solution at ASCO Meeting 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 3
... Reading a book can satisfy the crucial human need for ... 140 university students who were given 30 minutes to read ... Twilight or the wizard novel Harry Potter and ... of either vampires or wizards. The participants were then ...
... rising levels of cardiovascular disease (CVD) in the Asia Pacific ... the first time- the Society will send an official delegation ... The 18th edition of the APCC meeting will be ... 2011. The ESC deputation will present an educational programme called ...
... Chief of both the Division of Allergy and Inflammation and ... Center (BIDMC), is the recipient of an NIH MERIT ... A Professor of Medicine at Harvard Medical School, Weller received ... Functioning." An acronym for the Method to Extend Research ...
... is regarded as the most thorough way to ... procedure can also be painful. Scientists and engineers ... reduce patient discomfort while also ensuring the accuracy ... of Engineering led by Associate Professor of Mechanical ...
... accepted for publication in The Endocrine Society,s Journal of ... and white children with vitamin D deficiency both had higher ... levels of fat just under their skin and white children ... their internal organs. Studies in adults and children have ...
... The Scripps Research Institute and Tampa,s Moffitt Cancer ... study the formation and progression of prostate cancer. Of ... Scripps Research, with the remaining $138,380 supporting Moffitt Cancer ... Institutes of Health (NIH) will fund research to advance ...
Cached Medicine News:Health News:The European Society of Cardiology organizes educational program in Asia 2Health News:BIDMC's Peter Weller, M.D., receives NIH MERIT Award 2Health News:A less painful colonoscopy 2Health News:A less painful colonoscopy 3Health News:Vitamin D deficiency is associated with different types of obesity in black and white children 2Health News:Scripps Research wins more than $2 million to study prostate cancer 2
The RT-PLUS Solution is an axially supported rotation knee prosthesis for cemented implantation. The implant is available in three sizes, each of which can be combined with the next size up or down....
... Stabilized knee system was designed ... wear between all articulating surfaces ... associated with wear in order ... knee with normalized quadriceps and ...
... new generation of posterior stabilized knee ... the following: Patellar flange mates with ... machined condyles assure precise, repeatable kinematics ... and patella to reduce wear. Constant ...
... System offers a femoral option and tibial ... action that engages at 60 degrees of ... roll-back motion and allow for 130 degrees ... conjunction with the femur is designed to ...
Medicine Products: